{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-23-000004","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.742901+00:00","generated_at":"2026-06-18T14:07:26.060253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexicon Q4 net loss $30.5M; NDA for sotagliflozin on track for May PDUFA","bullets":["Net loss $30.5M ($0.16 per share) vs $25.6M ($0.17) in Q4 2021; full-year loss $101.9M ($0.62).","R&D expenses $14.0M (down from $16.5M); SG&A $16.3M (up from $8.8M) due to launch prep.","Cash and investments $138.4M as of Dec 31, 2022, up from $86.7M year-end 2021.","Sotagliflozin NDA for heart failure on track for May 2023 PDUFA date after FDA late-cycle review.","LX9211 showed consistent results in diabetic neuropathic pain; PHN study missed primary endpoint (p=0.12) but showed evidence of effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-23-000004","json":"https://secwatch.observer/filing/0001062822-23-000004.json","markdown":"https://secwatch.observer/filing/0001062822-23-000004.md","text":"https://secwatch.observer/filing/0001062822-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/lxrx-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:07:26.060253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8cdb94e7502de5a07ee88bf7e2f043915839003d","claim":"LEXICON PHARMACEUTICALS, INC. reported the three months ended December 31, 2022 results: net income Net loss of $30.5 million, or $0.16 per share, EPS $0.16 per share.","evidence_excerpt":"Net loss for the fourth quarter of 2022 was $30.5 million, or $0.16 per share, as compared to a net loss of $25.6 million, or $0.17 per share, in the corresponding period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Net income","value":"Net loss of $30.5 million, or $0.16 per share"},{"label":"EPS","value":"$0.16 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a390661f399189778de675fa3fd4dbb9b048c760","claim":"LEXICON PHARMACEUTICALS, INC. reported the full-year ended December 31, 2022 results: net income Net loss of $101.9 million, or $0.62 per share, EPS $0.62 per share.","evidence_excerpt":"Net loss for the full-year 2022 was $101.9 million, or $0.62 per share, as compared to a net loss of $87.8 million, or $0.60 per share in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2022"},{"label":"Net income","value":"Net loss of $101.9 million, or $0.62 per share"},{"label":"EPS","value":"$0.62 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}